Regeneron Pharmaceuticals
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 12:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 10-Q | 2026-10-30 | Read on SEC.gov |
| 8-K | 2026-10-30 | Read on SEC.gov |
| 8-K | 2026-10-06 | Read on SEC.gov |
| 8-K | 2026-09-30 | Read on SEC.gov |
| 10-Q | 2026-07-30 | Read on SEC.gov |
| 8-K | 2026-07-30 | Read on SEC.gov |
| 8-K | 2026-07-06 | Read on SEC.gov |
| 8-K | 2026-06-17 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 04:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $14.34B | Annual | 2025-12-31 | 2026-02-04 | 10-K |
| Net income | $4.50B | Annual | 2025-12-31 | 2026-02-04 | 10-K |
| Operating cash flow | $4.98B | Annual | 2025-12-31 | 2026-02-04 | 10-K |
| Total assets | $40.56B | As of | 2025-12-31 | 2026-02-04 | 10-K |
| Total liabilities | $9.30B | As of | 2025-12-31 | 2026-02-04 | 10-K |
| Stockholders’ equity | $31.26B | As of | 2025-12-31 | 2026-02-04 | 10-K |
| Cash and cash equivalents | $3.12B | As of | 2025-12-31 | 2026-02-04 | 10-K |
✦ Quant Financial Health how this is computed
- Altman Z-Score is 8.44, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
- Collaboration revenue is the largest reported line at 58.65% of revenue, across 10 reported segments.
- EYLEA HD ® follows at 13.66%, so the top line still matters most but isn’t the whole story.
Revenue annual, last 8 years
Latest year +0.99% YoY
Margins
- Gross margin
- 85.35%
- Operating margin
- 25.81%
- Net margin
- 31.41%
Key ratios & quality
- PEG ratioi
- 16.11
- Altman Z-Scorei
- 8.44
PEG uses trailing P/E against the 3-year net income growth rate (1.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.15B | 6.56B | 8.50B | 16.07B | 12.17B | 13.12B | 14.20B | 14.34B |
| Gross profit | 4.73B | 5.79B | 7.38B | 13.63B | 10.61B | 11.30B | 12.23B | 12.24B |
| Selling & admin expenses | 1.13B | 1.34B | 1.35B | 1.82B | 2.12B | 2.63B | 2.95B | 2.70B |
| Research & development | 1.47B | 2.45B | 2.74B | 2.86B | 3.59B | 4.44B | 5.13B | 5.85B |
| Operating profit | 2.53B | 2.21B | 3.58B | 8.99B | 4.99B | 4.23B | 4.09B | 3.70B |
| Pretax profit | 2.55B | 2.43B | 3.81B | 9.33B | 4.86B | 4.20B | 4.78B | 5.23B |
| Tax | 109.10M | 313.30M | 297.20M | 1.25B | 520.40M | 245.70M | 367.30M | 725.80M |
| Net profit | 2.44B | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | 4.41B | 4.50B |
| Basic EPS | 23 | 19 | 33 | 76 | 41 | 37 | 41 | 43 |
| Diluted EPS | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 3.68B | 3.75B | 3.88B | 3.61B | 4.29B | 5.12B |
| Gross profit | 3.15B | 3.23B | 3.30B | 2.94B | 3.71B | 4.54B |
| Selling & admin expenses | 634.20M | 657.80M | 775.00M | 647.70M | 662.10M | 677.80M |
| Research & development | 1.42B | 1.48B | 1.63B | 1.54B | 1.63B | 1.79B |
| Operating profit | 1.09B | 1.11B | 898.60M | 744.80M | 1.42B | 2.07B |
| Pretax profit | 1.52B | 1.76B | 1.04B | 831.20M | 1.53B | 2.28B |
| Tax | 127.10M | 303.30M | 199.10M | 104.00M | 230.90M | 335.40M |
| Net profit | 1.39B | 1.46B | 844.60M | 727.20M | 1.30B | 1.95B |
| Basic EPS | 13 | 14 | 8 | 7 | 13 | 19 |
| Diluted EPS | 12.81 | 13.62 | 7.86 | 6.75 | 12.23 | 18.45 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 6.45B | 7.69B | 9.78B | 14.01B | 15.88B | 19.48B | 18.66B | 18.02B |
| Cash & ST investments | 2.81B | 3.21B | 3.59B | 5.69B | 7.74B | 10.84B | 9.01B | 8.61B |
| Inventory | 1.15B | 1.42B | 1.92B | 1.95B | 2.40B | 2.58B | 3.09B | 3.20B |
| Total assets | 11.73B | 14.81B | 17.16B | 25.43B | 29.21B | 33.08B | 37.76B | 40.56B |
| Total current liabilities | 1.44B | 2.10B | 2.70B | 3.93B | 3.14B | 3.42B | 3.94B | 4.37B |
| Short-term debt | -- | -- | -- | 719.70M | -- | -- | -- | -- |
| Long-term debt | -- | -- | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.99B |
| Total liabilities | 2,977,200,000.00 | 3,715,500,000.00 | 6,138,000,000.00 | 6,666,000,000.00 | 6,550,500,000.00 | 7,107,100,000.00 | 8,405,800,000.00 | 9,301,800,000.00 |
| Total equity | 8.76B | 11.09B | 11.03B | 18.77B | 22.66B | 25.97B | 29.35B | 31.26B |
| Retained earnings | 5.25B | 7.38B | 10.89B | 18.97B | 23.31B | 27.26B | 31.67B | 35.80B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 16.86B | 17.98B | 18.02B | 18.21B | 18.45B | 20.80B |
| Cash & ST investments | 7.47B | 8.44B | 8.61B | 8.75B | 7.99B | 9.30B |
| Inventory | 3.21B | 3.25B | 3.20B | 3.10B | 3.08B | 1.99B |
| Total assets | 38.22B | 40.17B | 40.56B | 40.87B | 41.73B | 44.41B |
| Total current liabilities | 3.67B | 4.43B | 4.37B | 5.11B | 5.53B | 6.20B |
| Short-term debt | -- | -- | -- | 720.00M | 720.00M | 720.00M |
| Long-term debt | 1.99B | 1.99B | 1.99B | 1.99B | 1.99B | 1.99B |
| Total liabilities | 8,280,300,000.00 | 9,211,600,000.00 | 9,301,800,000.00 | 9,445,200,000.00 | 10,019,200,000.00 | 10,906,700,000.00 |
| Total equity | 29.94B | 30.96B | 31.26B | 31.42B | 31.71B | 33.50B |
| Retained earnings | 33.68B | 35.05B | 35.80B | 36.42B | 37.62B | 39.47B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.20B | 2.43B | 2.62B | 7.08B | 5.01B | 4.59B | 4.42B | 4.98B |
| Depreciation & amortization | 148.20M | 210.30M | 235.90M | 286.20M | 341.40M | 421.00M | 482.90M | 543.70M |
| Free cash flow | 1.81B | 2.00B | 2.00B | 6.53B | 3.40B | 3.67B | 3.54B | 3.77B |
| Dividends paid | -- | -- | -- | -- | -- | 0 | 0 | -370.30M |
| Stock buybacks / issuance | -77.10M | -252.10M | -3.95B | -1.01B | -1.01B | -1.79B | -2.17B | -3.33B |
| Ending cash balance | 1.48B | 1.63B | 2.21B | 2.90B | 3.12B | 2.74B | 2.49B | 3.12B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.14B | 1.62B | 1.17B | 1.08B | 813.00M | 1.78B |
| Depreciation & amortization | 135.10M | 136.70M | 145.00M | 123.20M | 123.70M | 121.00M |
| Free cash flow | 737.60M | 1.37B | 880.00M | 799.40M | 521.80M | 1.43B |
| Dividends paid | -92.60M | -91.20M | -92.70M | -97.80M | -96.80M | -95.70M |
| Stock buybacks / issuance | -1.04B | -626.70M | -687.40M | -704.40M | -1.13B | -194.50M |
| Ending cash balance | 2.02B | 2.51B | 3.12B | 2.97B | 2.47B | 3.67B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 32.81 | 21.32 | 31.77 | 54.21 | 20.94 | 16.26 | 15.95 | 14.87 |
| ROA %i | 23.85 | 15.94 | 21.98 | 37.91 | 15.88 | 12.69 | 12.46 | 11.50 |
| ROIC %i | 30.30 | 20.14 | 27.94 | 45.25 | 18.43 | 13.16 | 12.54 | 11.89 |
| 5-year avg ROE %i | 22.61 | 23.87 | 26.13 | 32.55 | 32.21 | 28.90 | 27.83 | 24.44 |
| EBIT margin %i | 38.47 | 31.28 | 45.51 | 58.38 | 40.40 | 32.57 | 34.05 | 36.77 |
| FCF / sales %i | 27.00 | 25.44 | 23.58 | 40.63 | 27.91 | 27.96 | 24.92 | 26.25 |
| Current ratioi | 4.47 | 3.67 | 3.63 | 3.56 | 5.06 | 5.69 | 4.73 | 4.13 |
| Quick ratioi | 3.50 | 2.86 | 2.86 | 2.98 | 4.16 | 4.82 | 3.86 | 3.28 |
| Debt / assetsi | 6.04 | 4.82 | 15.71 | 10.61 | 9.25 | 8.17 | 7.16 | 6.67 |
| LT debt / equityi | 8.09 | 6.44 | 24.45 | 10.55 | 11.92 | 10.41 | 9.21 | 8.66 |
| Interest coveragei | 91.55 | 81.43 | 67.97 | 163.75 | 82.80 | 58.52 | 87.59 | 120.42 |
| Revenue CAGR (3Y) %i | 7.83 | 10.50 | 13.11 | 46.18 | 22.90 | 15.57 | -4.04 | 5.62 |
| Net income CAGR (3Y) %i | 56.64 | 33.19 | 43.12 | 48.93 | 27.04 | 4.02 | -18.25 | 1.26 |
| FCF CAGR (3Y) %i | 40.53 | 27.11 | 24.65 | 53.31 | 19.32 | 22.33 | -18.47 | 3.48 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 15.34 | 15.19 | 14.87 | 14.55 | 14.04 | 14.95 |
| ROA %i | 12.00 | 11.80 | 11.50 | 11.28 | 10.83 | 11.39 |
| ROIC %i | 12.07 | 12.14 | 11.89 | 11.48 | 11.09 | 11.98 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 34.55 | 36.41 | 36.77 | 34.89 | 33.61 | 33.93 |
| FCF / sales %i | 25.02 | 27.24 | 26.25 | 25.41 | 23.01 | 21.47 |
| Current ratioi | 4.60 | 4.06 | 4.13 | 3.57 | 3.34 | 3.35 |
| Quick ratioi | 3.57 | 3.19 | 3.28 | 2.84 | 2.63 | 2.72 |
| Debt / assetsi | 7.08 | 6.74 | 6.67 | 6.62 | 6.49 | 6.10 |
| LT debt / equityi | 9.04 | 8.74 | 8.66 | 6.32 | 6.26 | 5.93 |
| Interest coveragei | 134.19 | 123.21 | 120.42 | 108.44 | 94.25 | 122.77 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Regeneron Pharmaceuticals discussion 0 comments